2025
Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill
Munroe E, Spicer A, Castellvi-Font A, Zalucky A, Dianti J, Linck E, Talisa V, Urner M, Angus D, Baedorf-Kassis E, Blette B, Bos L, Buell K, Casey J, Calfee C, Del Sorbo L, Estenssoro E, Ferguson N, Giblon R, Granholm A, Harhay M, Heath A, Hodgson C, Houle T, Jiang C, Kramer L, Lawler P, Leligdowicz A, Li F, Liu K, Maiga A, Maslove D, McArthur C, McAuley D, Neto A, Oosthuysen C, Perner A, Prescott H, Rochwerg B, Sahetya S, Samoilenko M, Schnitzer M, Seitz K, Shah F, Shankar-Hari M, Sinha P, Slutsky A, Qian E, Webb S, Young P, Zampieri F, Zarychanski R, Fan E, Semler M, Churpek M, Goligher E, investigators P, Group E. Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill. The Lancet Respiratory Medicine 2025, 13: 556-568. PMID: 40250459, PMCID: PMC12362495, DOI: 10.1016/s2213-2600(25)00054-2.Peer-Reviewed Original ResearchConceptsAverage treatment effectCritical careHeterogeneity of treatment effectsTreatment decisionsTreatment effectsCritical care syndromesResponse to treatmentClinical careRandomised clinical trialsCareRandomised trialsEffects of treatmentTreatment responseClinical trialsAggregate differencesPatientsOutcomesPersonalised medicineTreatmentEffect ITrials
2022
Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment
Ghazi L, Li F, Chen X, Simonov M, Yamamoto Y, Biswas A, Hanna J, Shah T, Townsend R, Peixoto A, Wilson FP. Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Journal Of Clinical Hypertension 2022, 24: 339-349. PMID: 35174627, PMCID: PMC8925013, DOI: 10.1111/jch.14431.Peer-Reviewed Original ResearchConceptsSevere hypertensionBlood pressure responseBP elevationUntreated patientsCox proportional hazards modelRetrospective cohort studyPressure responseProportional hazards modelAntihypertensive treatmentInpatient hypertensionMore comorbiditiesPossible overtreatmentHospitalized adultsCohort studyHypertension prevalenceArterial pressureHospitalized patientsTreatment guidelinesHypertensionGreater rateHazards modelPatientsAntihypertensivesTreatmentAdmission
2021
Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas
Wegienka G, Stewart E, Nicholson W, Zhang S, Li F, Thomas L, Spies J, Venable S, Laughlin-Tommaso S, Diamond M, Anchan R, Maxwell G, Marsh E, Myers E, Vines A, Wise L, Wallace K, Jacoby V. Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas. Journal Of Women's Health 2021, 30: 355-366. PMID: 33524308, DOI: 10.1089/jwh.2020.8634.Peer-Reviewed Original ResearchConceptsUterine fibroidsWhite womenBlack womenUterine-sparing treatmentClinical sitesTertiary care centerPatients' medical recordsRandom effects logistic regressionTreatment RegistryHysterectomyUF symptomsSubgroup analysisTreatment selectionConclusion:Quality of lifeWorse symptomsMedical recordsCare centerMyomectomyLogistic regressionWomenResults:Evaluate differencesTreatmentWhite counterparts
2017
Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study
Assel MJ, Li F, Wang Y, Allen AS, Baggerly KA, Vickers AJ. Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology 2017, 125: 391-397. PMID: 29032853, PMCID: PMC5820191, DOI: 10.1016/j.ophtha.2017.09.008.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationAdvanced age-related macular degenerationEye Disease StudyGenotype-treatment interactionDisease StudyHigh-risk patientsStandard careAMD progressionBaseline predictorsMacular degenerationTreatment responseGenotype subgroupsAREDS participantsPatientsGenetic polymorphismsSingle nucleotide polymorphismsCategory 1Negative resultsAgePopulation of interestTreatmentMultiple testingProgressionNucleotide polymorphismsAntioxidants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply